3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
4
Recurrence
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Nodule
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Postoperative Complications
1
Pneumonia
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Obesity
1
Neoplasms, Plasma Cell
1
Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Extranodal NK-T-Cell
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Lung Diseases, Interstitial
1
Locally Advanced Breast Cancer
1
Intermittent Fasting
1
Hypothyroidism
1
Hyperthyroidism
1
Hepatitis
1
Interventions
Gemcitabine
82
Cisplatin
52
Oxaliplatin
36
lenvatinib
24
durvalumab
22
Capecitabine
22
Fluorouracil
20
Leucovorin
15
tislelizumab
11
pembrolizumab
10
apatinib
10
Radiotherapy
10
Albumin-Bound Paclitaxel
10
Radiofrequency Ablation
9
Magnetic Resonance Spectroscopy
9
Irinotecan
9
Floxuridine
9
Liver Transplantation
8
Drug Therapy
8
Cholangiopancreatography, Endoscopic Retrograde
8
130-nm albumin-bound paclitaxel
8
Taxes
7
Platinum
7
Photochemotherapy
7
Panitumumab
7
Biopsy
7
1,2-diaminocyclohexaneplatinum II citrate
7
tremelimumab
6
pemigatinib
6
camrelizumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cholangiocarcinoma
×
Clinical Protocols
×
Clear all
NCT05557578
2025-02-11
GOT
Zhejiang Cancer Hospital
Phase 2
Recruiting
20 enrolled